Press release
Asia-Pacific Human Insulin Market to Grow at a CAGR of 8.12% Until 2030 | Becton, Dickinson and Company (BD), and Biocon Limited
Latest Market Study report by MarkNtel Advisors: Leading market research company, Title "Asia-Pacific Human Insulin Market- By Type (Human Insulin Biologics, Intermediate Acting, Short Acting, Premixed), Insulin Analogue & Biosimilar, [Long Acting, Rapid Acting, Premixed]), By Application, (Diabetes Type 1, Diabetes Type 2)," and other forecast 2024-30". This detailed report provides a thorough look at the industry, covering key aspects like the Asia-Pacific Human Insulin Market Size, its growth in share, development, and the top companies involved. It examines what's driving the market, using historical, current, and projected data, as well as emerging trends, technology updates, important insights, recent developments, potential limitations, and other factors that will influence the industry's direction in the future.How Big is the Asia-Pacific Human Insulin Industry?
Asia-Pacific Human Insulin Market is estimated to grow at a CAGR of around 8.12% during the forecast period, i.e., 2024-30.
Ask Our Sales Team for a Free Sample Of the Report - https://www.marknteladvisors.com/query/request-sample/apac-human-insulin-market.html
Factors Influencing the Growth of the Asia-Pacific Human Insulin Industry:
Surging Prevalence of Diabetes Boosting the Human Insulin Market - The Asia-Pacific Human Insulin Market has witnessed robust growth driven by a surge in diabetes prevalence over the historical years. This has been primarily attributed to factors such as changing lifestyles, increased obesity rates, and an aging population. Asia-Pacific aging demographics have also played a pivotal role as older individuals are more prone to diabetes. According to the Economic and Social Commission for Asia and the Pacific, the number of older persons is projected to more than double, from around 630 million in 2020 to about 1.3 billion by 2050. Hence, as the world experiences a demographic shift towards an older age structure, the prevalence of diabetes is on the rise. This demographic trend amplifies the demand for human insulin, which has aided in driving the Asia-Pacific Human Insulin Market.
Name of Leading Asia-Pacific Human Insulin Companies in the Market
> Novo Nordisk A/S
> Eli Lilly and Company
> Sanofi
> Biocon
> Gan & Lee Pharmaceuticals Co. Ltd
> Wockhardt
> Lupin
> Eris Lifesciences Ltd
> Tonghua Dongbao Pharmaceutical Co., Ltd.
> The United Laboratories International Holdings Limited
Visit to See Our Complete Study [Include Description + TOC], - https://www.marknteladvisors.com/research-library/apac-human-insulin-market.html
Segmentation Summary - Asia-Pacific Human Insulin Market
The breakdown of the Asia-Pacific Human Insulin market into different segments provides a quick overview. It helps businesses understand what customers prefer and where they are located. By dividing the market into smaller groups based on purchasing habits and geography, companies can improve their business strategies. This summary offers a straightforward guide to better understanding the market.
By Type
> Human Insulin Biologics - Market Size & Forecast 2019-2030, USD Million
> Insulin Analogue & Biosimilar - Market Size & Forecast 2019-2030, USD Million
By Application
> Diabetes Type 1- Market Size & Forecast 2019-2030, USD Million
> Diabetes Type 2- Market Size & Forecast 2019-2030, USD Million
By End Users
> Hospital/Clinics- Market Size & Forecast 2019-2030, USD Million
> Home/Personal- Market Size & Forecast 2019-2030, USD Million
By Distribution Channel
> Hospital Pharmacies- Market Size & Forecast 2019-2030, USD Million
> Retail Pharmacies- Market Size & Forecast 2019-2030, USD Million
> Online Pharmacies- Market Size & Forecast 2019-2030, USD Million
Geographically Insight: Asia-Pacific Human Insulin Market
Geographically, the Asia-Pacific Human Insulin Market expands across:
* China
* India
* Japan
* South Korea
* Southeast Asia
* Australia
* Rest of Asia-Pacific
The rising geriatric population and increased prevalence of diabetes in China have accelerated the domestic consumption of human insulin during the historical years. As consumers age, they are more susceptible to developing type 2 diabetes due to factors such as decreased physical activity, changes in metabolism, and other age-related health conditions.
If you need more specific details that aren't already in the report, we're here to help! Just Click [ https://www.marknteladvisors.com/query/request-customization/apac-human-insulin-market.html ] the link and "Sent Your Inquiry" to let us know what you're looking for, and we'll be happy to customize the report to meet your needs.
Frequently Asking Question: GCC P2P Payment Market
* What are common indicators of market growth?
* Where can I access reliable market reports?
* What are the anticipated growth projections for the GCC P2P Payment market in the next six years?
* What geographic regions are expected to experience the most significant market growth in the future?
Browse Other Reports:
* https://www.marknteladvisors.com/research-library/global-mechanical-seals-market.html
* https://www.marknteladvisors.com/research-library/india-diesel-generators-market.html
* https://www.marknteladvisors.com/research-library/global-graphene-market.html
* https://www.marknteladvisors.com/research-library/global-precision-medicine-market.html
* https://www.marknteladvisors.com/research-library/marine-collagen-market.html
Call 📞 +1 628 895 8081 +91 120 4278433
Email: 📧 sales@marknteladvisors.com
Address: 🏢 564 Prospect St, B9, New Haven, Connecticut, USA-06511
MarkNtel Advisors is a leading consulting, data analytics, and market research company that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.
We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asia-Pacific Human Insulin Market to Grow at a CAGR of 8.12% Until 2030 | Becton, Dickinson and Company (BD), and Biocon Limited here
News-ID: 3403701 • Views: …
More Releases for Insulin
Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,…
Bluetooth connected smart insulin pens represent the future of insulin delivery …
Increasing pool of diabetic patients witnessed across the globe has prompted leading manufacturers of medical devices towards development of ground-breaking products. Smart insulin pens are among such devices that have revolutionised the global market for diabetic injection pens. A recent study published by Future Market Insights projects that the global smart insulin pens market, which is currently valued at US$ 0.86 Mn, will expand vigorously at 17.9% CAGR through the…
Insulin pump Market Explore Future Growth 2018-2026 by Global Type-Traditional i …
Insulin pump is a portable device attached to the body that continuously delivers preset amounts of short or rapid acting insulin in the body to control diabetes. Insulin therapy is required in type 1 diabetes and sometime in type 2 diabetes. It serves as an effective alternative to insulin injections. Furthermore, insulin pump delivers the insulin according to the need of body as basal rate, where small amount of insulin…
Insulin Drug and Delivery Technologies Market Report 2018: Segmentation by Produ …
Global Insulin Drug and Delivery Technologies market research report provides company profile for Julphar, Ypsomed, Becton, Dickinson and Company, Sanofi, Eli Lilly and Company, Biocon and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc.…
Smart Insulin Pens Market: Bluetooth Connected Smart Insulin Pens Allow Effectiv …
By connectivity, the Bluetooth connected smart insulin pen segment is expected to account for a value share of US$ 0.276 Mn in 2017. The segment is expected to reach a little more than US$ 2 Mn by 2027 end, registering the highest CAGR of 23.2% over the forecast period. Bluetooth connected smart insulin pens represent the future of insulin delivery devices. Such devices have an inbuilt Bluetooth connectivity feature allowing…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…